Company: CYTK
Filing Date: 2025-04-10
Form Type: DEF 14A
Source: 0001140361-25-013167
Chunk: 70

Company: CYTOKINETICS INC
Filing Date: 2025-04-10
Form: DEF 14A
Chunk 70
---
 relative to these goals. The Compensation Committee does not use a rigid formula in determining the Company’s level of achievement, but instead considers:

| • | the degree of success achieved for each corporate goal, comparing actual results against the pre-determined deliverables associated with each objective; |

| • | the difficulty of the goal; |

| • | whether significant unforeseen obstacles or favorable circumstances altered the expected difficulty of achieving the desired results; |

| • | other factors that may have made the stated goals more or less important to our success; and |

| • | other accomplishments by us during the year or other factors that, although not included as part of the formal goals, are nonetheless deemed important to our near- and long-term success. |

The Compensation Committee does not assign weights in these assessments but uses its discretion and judgment to determine a percentage that it believes fairly represents the achievement level for the year and considers organizational impact. In February 2025, the Compensation Committee, after exercising its discretion and based on progress in the advancement of our skeletal and cardiac muscle programs, the achievement of research program milestones, the achievement of other financing objections and certain research goals, determined that we had an overall corporate achievement level of 110% for 2025.

| 48 |     | Cytokinetics, Inc.|2025 Proxy Statement |

TABLE OF CONTENTS Executive Compensation

Individual Goals. Individual goals for each named executive officer are derived from the corporate goals that relate to his or her functional area, except for our CEO, who has no individual goals apart from the corporate goals. Our CEO established the individual goals for 2024 with each other named executive officer described below based on the relevant corporate goals and key functional area priorities for the year.

| • | Mr. Callos's individual goals for 2024 included: |

| • | Goals attributable to European Commercial Launch Readiness for Aficamten: |

| • | Board of Directors endorsed go-to-market plan for the EU; |

| • | Initiate implementation of supply chain strategy through set up EU distribution schemes and select 3PL partner; |

| • | Prepare and submit wholesaler distributor authorization for EU; and |

| • | Open EU headquarters, hire budgeted leadership positions, and establish German management team. |

| • | Goals attributable to Aficamten Global Launch Readiness: |

| • | Global Value Dossier Completed; |

| • | Define global launch strategy for rollout of MAPLE inclusive of positioning and messaging; |

| • | Global and regional pricing governance